USE OF LONG-ACTING RECOMBINANT HUMAN SOLUBLE TUMOR NECROSIS FACTOR α RECEPTOR IN MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PROPHYLAXIS OF HEPATIC FAILURE
THE PRESENT INVENTION BELONGS TO THE FIELD OF THE APPLICATION OF GENETIC ENGINEERING AND GENE FUNCTION, AND IT IS DIRECTED TO A NEW MEDICAL USE OF THE GENE ENCODING THE RECOMBINANT SOLUBLE TUMOR NECROSIS FACTOR α RECEPTOR (HusTNFR). THE PRESENT INVENTION MADE INTERVENTION TO FULMINANT HEPATIC FAILURE IN MICE BY USE OF THE LONG-ACTING RECOMBINANT HUMAN SOLUBLE TUMOR NECROSIS FACTOR α RECEPTOR AND THE CLASSIC ANIMAL MODELS OF ACUTE AND SUB-ACUTE HEPATIC FAILURE. THE RESULTS SHOWED THAT THE LONG-ACTING SOLUBLE TUMOR NECROSIS FACTOR α RECEPTOR OF THE PRESENT INVENTION HAS A HALF-LIFE EXTENDED MORE THAN 10 TIMES, AND IT SIGNIFICANTLY DECREASED THE MORTALITY OF MODEL ANIMALS AND HAS SUPERIOR THERAPEUTIC EFFECT FOR THE TREATMENT AND/OR PROPHYLAXIS OF ACUTE AND SUB-ACUTE HEPATIC FAILURE IN MODEL ANIMALS. THESE RECEPTORS HAVE A NOTICEABLE THERAPEUTIC EFFECT FOR THE TREATMENT AND/OR PROPHYLAXIS OF ACUTE AND SUB-ACUTE HEPATIC FAILURE IN COMPARISON WITH THE NON-LONG-ACTING HusTNFR.
